Correction To: FDA and EMA Biosimilar Approvals

Journal of General Internal Medicine - Germany
doi 10.1007/s11606-019-05558-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

2017 FDA Drug Approvals

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2018English

FDA Approves First Biosimilar to Treat Cancer

Cancer Discovery
Oncology
2017English

FDA-Approved Biosimilar Insulin

Journal of diabetes science and technology
Internal MedicineEndocrinologyBioengineeringBiomedical EngineeringMetabolismDiabetes
2014English

Pcn310 - Survival in Cancer Clinical Trials: A Comparison of Ema Approvals and Nice Recommendations.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

FDA Town Hall: New Drug Approvals in Gastrointestinal Disease (2018-2019)

Gastroenterology
HepatologyGastroenterology
2020English

FDA Reported Use of Patient Experience Data in 2018 Drug Approvals

Therapeutic Innovation and Regulatory Science
PharmacologyPublic HealthEnvironmentalToxicologyPharmaceuticsOccupational Health
2019English

Preclinical Efficacy in Therapeutic Area Guidelines From FDA and EMA: A Cross-Sectional Study

British Journal of Pharmacology
Pharmacology
2018English

Pnd115 - A Comparison of Fda and Ema Guidance on Medicines for the Treatment of Alzheimer’s Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Correction: Nods for Atezolizumab and Nivolumab From FDA

Cancer Discovery
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy